Clinical trial Recruiting at 37 sites Phase 2 Interventional Ages 18 to 70

VIM0423 for adults with isolated dystonia affecting multiple body regions

Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia (Stride Dystonia)

Run by Vima Therapeutics · NCT07304089 · Data updated 2026-11-12

This trial will test a once-daily oral medicine called VIM0423 to see if it reduces dystonia symptoms and improves daily function in adults with isolated dystonia that affects two or more body regions.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment100 (estimated)
SponsorVima Therapeutics
Industry-sponsored
Locations45 sites (Birmingham, Alabama and 44 other locations)
StatusRecruiting
StartedFebruary 5, 2026
Main results expectedMarch 2027
Study endsMay 2027
Registry record updatedOctober 26, 2026
Trial IDNCT07304089 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18–65 with a clinical diagnosis of isolated dystonia for at least one year and two or more affected body regions who meet baseline rating-scale criteria (and stable or no botulinum toxin treatment per protocol) are ideal candidates.

Probably not a fit

People whose dystonia affects only a single region, those outside the 18–65 age range, pregnant individuals, or those with secondary dystonia are unlikely to be eligible or to benefit from this trial.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Stride Dystonia (VIM0423-201) is a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial testing once-daily oral VIM0423 in adults with isolated dystonia affecting two or more body regions. VIM0423 is intended to correct a chemical imbalance in brain regions thought to cause dystonia. About 120 participants will be randomized to VIM0423 or placebo and followed for measures of symptom severity, daily function, and quality of life while safety and tolerability are monitored. Key outcome measures include dystonia rating scales (e.g., BFM), clinician global impression, patient-reported function, and adverse events.

Why it matters

Potential benefit: If effective, VIM0423 could provide the first oral therapy that reduces dystonia symptoms across multiple body regions and improves daily function and quality of life.

How similar studies have gone: Approved botulinum toxin injections work for some focal dystonias, and prior oral medications have given limited or inconsistent benefit, so an oral drug that treats multiple regions would be a relatively novel but plausible advance.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participant must be male or nonpregnant female between 18 and 70 years of age (inclusive) at Visit 1 (Screening).
* The participant has a clinical diagnosis of isolated dystonia with symptoms consistent with dystonia for at least one year prior to Visit 1 (Screening); has two or more body regions affected by dystonia at Visit 1 (Screening); and has been confirmed by Investigator and Enrollment Authorization Committee.
* The participant may be untreated with BoNT; OR if the participant is being treated with BoNT as part of their standard of care for dystonia, they must meet protocol-specified criteria.
* The participants must meet protocol-specified requirements for baseline scores on the BFM and CGI-S.

Where it's running

  • Vima Site #033
    Birmingham, Alabama, United States
    Recruiting
  • Vima Site #039
    Scottsdale, Arizona, United States
    Recruiting
  • Vima Site #004
    Scottsdale, Arizona, United States
    Recruiting
  • Vima Site #028
    Sun City, Arizona, United States
    Recruiting
  • Vima Site #042
    Irvine, California, United States
    Recruiting
  • Vima Site #030
    Los Angeles, California, United States
    Recruiting
Show 39 more locations
  • Vima Site #019
    Denver, Colorado, United States
    Recruiting
  • Vima Site #009
    Gainesville, Florida, United States
    Recruiting
  • Vima Site #008
    Miami, Florida, United States
    Recruiting
  • Vima Site #031
    Orlando, Florida, United States
    Recruiting
  • Vima Site #005
    Atlanta, Georgia, United States
    Recruiting
  • Vima Site #027
    Chicago, Illinois, United States
    Recruiting
  • Vima Site #041
    Overland Park, Kansas, United States
    Recruiting
  • Vima Site #043
    Baltimore, Maryland, United States
    Recruiting
  • Vima Site #007
    Olney, Maryland, United States
    Recruiting
  • Vima Site #032
    Boston, Massachusetts, United States
    Recruiting
  • Vima Site #037
    East Lansing, Michigan, United States
    Recruiting
  • Vima Site #002
    Farmington Hills, Michigan, United States
    Recruiting
  • Vima Site #038
    St Louis, Missouri, United States
    Recruiting
  • Vima Site #014
    Albuquerque, New Mexico, United States
    Recruiting
  • Vima Site #018
    New York, New York, United States
    Recruiting
  • Vima Site #024
    New York, New York, United States
    Recruiting
  • Vima Site #036
    Rochester, New York, United States
    Recruiting
  • Vima Site #040
    Fayetteville, North Carolina, United States
    Recruiting
  • Vima Site #035
    Cincinnati, Ohio, United States
    Recruiting
  • Vima Site #029
    Portland, Oregon, United States
    Recruiting
  • Vima Site #020
    Philadelphia, Pennsylvania, United States
    Recruiting
  • Vima Site #021
    Charleston, South Carolina, United States
    Recruiting
  • Vima Site #016
    Memphis, Tennessee, United States
    Recruiting
  • Vima Site #006
    Nashville, Tennessee, United States
    Recruiting
  • Vima Site #025
    Dallas, Texas, United States
    Recruiting
  • Vima Site #026
    Georgetown, Texas, United States
    Recruiting
  • Vima Site #012
    Houston, Texas, United States
    Recruiting
  • Vima Site #013
    Houston, Texas, United States
    Recruiting
  • Vima Site #011
    Richmond, Virginia, United States
    Recruiting
  • Vima Site #023
    Kirkland, Washington, United States
    Recruiting
  • Vima Site #015
    Spokane, Washington, United States
    Recruiting
  • Vima Site #061
    Sacramento, California, United States
    Not yet recruiting
  • Vima Site #056
    Aurora, Colorado, United States
    Not yet recruiting
  • Vima Site #069
    Vernon, Connecticut, United States
    Not yet recruiting
  • Vima Site #055
    Amherst, New York, United States
    Not yet recruiting
  • Vima Site #059
    Calgary, Alberta, Canada
    Not yet recruiting
  • Vima Site #068
    Vancouver, British Columbia, Canada
    Not yet recruiting
  • Vima Site #070
    Ottawa, Ontario, Canada
    Not yet recruiting
  • Vima Site #060
    Toronto, Ontario, Canada
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.